Tag: dna

Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20insApproval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which...

INOVIO Announces Proposed Public Offering

PLYMOUTH MEETING, Pa., July 2, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to...

ARGAN: HALF-YEAR ASSESSMENT LIQUIDITY CONTRACT WITH ODDO – H1 2025

Press release – Neuilly-sur-Seine, Wednesday, July 2, 2025 - 5.45 pm

SeekInClarity: Blood-Based Multi-Omics Test Offers Promising Advance in Monitoring Cancer Treatment Response

SAN DIEGO, July 2, 2025 /PRNewswire/ -- A new prospective study published in BMC Cancer demonstrates that a novel blood-based multi-omics test, SeekInClarity, can accurately...

Direct Meds Launches Company-Wide AI Program to Scale Patient Care Amid Explosive Growth

Direct Meds LLC, a fast-scaling telemedicine provider serving the US and Canada, today announced a company-wide deployment of artificial intelligence (AI).

Hemispherian Receives U.S. FDA Orphan Drug Designation for GLIX1 for the Treatment of Malignant Glioma

OSLO, Norway, July 1, 2025 /PRNewswire/ -- Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, announced today that the U.S....

Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants

VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”) announces that it will apply to the TSX Venture Exchange (the “Exchange”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsDna

《The 36th Golden Melody Awards》

Form 8.5 (EPT/RI) – Dowlais Group plc

ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT Q2 2025

Tag: dna

Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

INOVIO Announces Proposed Public Offering

ARGAN: HALF-YEAR ASSESSMENT LIQUIDITY CONTRACT WITH ODDO – H1 2025

SeekInClarity: Blood-Based Multi-Omics Test Offers Promising Advance in Monitoring Cancer Treatment Response

Direct Meds Launches Company-Wide AI Program to Scale Patient Care Amid Explosive Growth

Hemispherian Receives U.S. FDA Orphan Drug Designation for GLIX1 for the Treatment of Malignant Glioma

Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants

Rapid Diagnostics Market to Reach $24.28 Billion by 2032, Growing at a CAGR of 6.6% from 2025, Says Meticulous Research®

Altezza Travel and Scientists Discover Africa’s Highest-Living Frog on Mount Kilimanjaro

Merrell Advances Running Innovation with the Launch of the High-Tech ProMorph Hybrid

GOVERNMENT OF CANADA EXTENDS MDA SPACE CONTRACT PROVIDING CONTINUOUS SPACE-BASED MARITIME AWARENESS AND SECURITY

GOVERNMENT OF CANADA EXTENDS MDA SPACE CONTRACT PROVIDING CONTINUOUS SPACE-BASED MARITIME AWARENESS AND SECURITY

Cato Networks Raises $359 Million at a Valuation of More Than $4.8 Billion

Cato Networks Raises $359 Million at a Valuation of More Than $4.8 Billion

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us